241 related articles for article (PubMed ID: 37127558)
21. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Croom KF; Scott LJ
Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
[TBL] [Abstract][Full Text] [Related]
23. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
24. Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
Kovacs TO; Freston JW; Haber MM; Atkinson S; Hunt B; Peura DA
Dig Dis Sci; 2010 May; 55(5):1325-36. PubMed ID: 19582579
[TBL] [Abstract][Full Text] [Related]
25. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Kovacs TO; Freston JW; Haber MM; Hunt B; Atkinson S; Peura DA
Dig Dis Sci; 2009 Aug; 54(8):1693-701. PubMed ID: 19267194
[TBL] [Abstract][Full Text] [Related]
27. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Hou X; Meng F; Wang J; Sha W; Chiu CT; Chung WC; Gu L; Kudou K; Chong CF; Zhang S
J Gastroenterol Hepatol; 2022 Jul; 37(7):1275-1283. PubMed ID: 35342997
[TBL] [Abstract][Full Text] [Related]
28. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
[TBL] [Abstract][Full Text] [Related]
29. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
[TBL] [Abstract][Full Text] [Related]
30. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Gough AL; Long RG; Cooper BT; Fosters CS; Garrett AD; Langworthy CH
Aliment Pharmacol Ther; 1996 Aug; 10(4):529-39. PubMed ID: 8853756
[TBL] [Abstract][Full Text] [Related]
31. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Gremse DA
Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
[TBL] [Abstract][Full Text] [Related]
33. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Haber MM; Hunt B; Freston JW; Peura DA; Kovacs TO; Atkinson S; Hisada M
Aliment Pharmacol Ther; 2010 Jul; 32(1):83-96. PubMed ID: 20345509
[TBL] [Abstract][Full Text] [Related]
34. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Mee AS; Rowley JL
Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
[TBL] [Abstract][Full Text] [Related]
35. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Fennerty MB; Johanson JF; Hwang C; Sostek M
Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
[TBL] [Abstract][Full Text] [Related]
37. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
38. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
39. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Kawamura M; Ohara S; Koike T; Iijima K; Suzuki J; Kayaba S; Noguchi K; Hamada S; Noguchi M; Shimosegawa T;
Aliment Pharmacol Ther; 2003 Apr; 17(7):965-73. PubMed ID: 12656699
[TBL] [Abstract][Full Text] [Related]
40. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
